Top

Published in:

01-06-2021 | Sarcoidosis | Editorial

Potential roles of ¹²³I-BMIPP SPECT to assess cardiac sarcoidosis

Authors: Osamu Manabe, MD, PhD, Nagara Tamaki, MD, PhD

Published in: Journal of Nuclear Cardiology | Issue 3/2021

Excerpt

Under normal fasting conditions, the healthy heart derives its energy from a variety of oxidizable substrates, including fatty acids, glucose, lactate, and amino acids. Among them, 60-70% of the energy production is obtained from fatty acid oxidation, and most of the remaining energy comes from glucose metabolism in the healthy myocardium. Under ischemic conditions, oxidative metabolism of free fatty acids is decreased due to the requirement of more oxygen compared to glucose for β-oxidation in mitochondria. …

Knapp FF Jr, Goodman MM, Callahan AP, Kirsch G. Radioiodinated 15-(p-iodophenyl)-3,3-dimethylpentadecanoic acid: A useful new agent to evaluate myocardial fatty acid uptake. J Nucl Med 1986;27(4):521–31.PubMed

Torizuka K, Yonekura Y, Nishimura T, Tamaki N, Uehara T, Ikekubo K, et al. A Phase 1 study of beta-methyl-p-(123I)-iodophenyl-pentadecanoic acid (123I-BMIPP)Kaku igaku. Jpn J Nucl Med 1991;28(7):681–90.

Kurata C, Tawarahara K, Taguchi T, Aoshima S, Kobayashi A, Yamazaki N, et al. Myocardial emission computed tomography with iodine-123-labeled beta-methyl-branched fatty acid in patients with hypertrophic cardiomyopathy. J Nucl Med 1992;33(1):6–13.PubMed

Terasaki F, Azuma A, Anzai T, Ishizaka N, Ishida Y, Isobe M, et al. JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis- digest version. Circ J 2019;83(11):2329–88.CrossRef

Momose M, Fukushima K, Kondo C, Serizawa N, Suzuki A, Abe K, et al. Diagnosis and detection of myocardial injury in active cardiac sarcoidosis-significance of myocardial fatty acid metabolism and myocardial perfusion mismatch. Circ J 2015;79(12):2669–76.CrossRef

Koyanagawa K, Naya M, Aikawa T, Manabe O, Furuya S, Kuzume M, et al. The rate of myocardial perfusion recovery after steroid therapy and its implication for cardiac events in cardiac sarcoidosis and primarily preserved left ventricular ejection fraction. J Nucl Med 2019.

Koiwa H, Tsujino I, Ohira H, Yoshinaga K, Otsuka N, Nishimura M. Images in cardiovascular medicine: Imaging of cardiac sarcoid lesions using fasting cardiac 18F-fluorodeoxyglucose positron emission tomography: An autopsy case. Circulation 2010;122(5):535–6.CrossRef

Sperry BW, Tamarappoo BK, Oldan JD, Javed O, Culver DA, Brunken R, et al. Prognostic impact of extent, severity, and heterogeneity of abnormalities on (18)F-FDG PET scans for suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2018;11(2 Pt 2):336–45.CrossRef

Manabe O, Ohira H, Hirata K, Hayashi S, Naya M, Tsujino I, et al. Use of (18)F-FDG PET/CT texture analysis to diagnose cardiac sarcoidosis. Eur J Nucl Med Mol Imaging 2019;46(6):1240–7.CrossRef

10.

Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11(7):1305–23.CrossRef

11.

Greulich S, Deluigi CC, Gloekler S, Wahl A, Zurn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2013;6(4):501–11.CrossRef

12.

Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63(4):329–36.CrossRef

13.

Tuominen H, Haarala A, Tikkakoski A, Kahonen M, Nikus K, Sipila K. FDG-PET in possible cardiac sarcoidosis: Right ventricular uptake and high total cardiac metabolic activity predict cardiovascular events. J Nucl Cardiol 2021;28(1):199–205.CrossRef

14.

Laudicella R, Minutoli F, Baldari S. Prognostic insights of molecular imaging in cardiac sarcoidosis. J Nucl Cardiol 2021;28(1):206–8.CrossRef

15.

Yamamoto A, Nagao M, Watanabe E, Imamura Y, Suzuki A, Fukushima K, et al. Prognosis and recurrence in cardiac sarcoidosis: Serial assessment of BMIPP SPECT and FDG-PET. J Nucl Cardiol 2021.

16.

Ramirez R, Trivieri M, Fayad ZA, Ahmadi A, Narula J, Argulian E. Advanced imaging in cardiac sarcoidosis. J Nucl Med 2019;60(7):892–8.CrossRef

Title: Potential roles of 123I-BMIPP SPECT to assess cardiac sarcoidosis
Authors: Osamu Manabe, MD, PhD
Nagara Tamaki, MD, PhD
Publication date: 01-06-2021
Publisher: Springer International Publishing
Keywords: Sarcoidosis
Sarcoidosis
Positron Emission Tomography
Published in: Journal of Nuclear Cardiology / Issue 3/2021
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-021-02654-2

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Potential roles of ¹²³I-BMIPP SPECT to assess cardiac sarcoidosis

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2021

Multimodality imaging for diagnosis in primary cardiac angiosarcoma

A case of primary cardiac lymphoma: Difficult to diagnose

Thymic carcinoid mimicking mediastinal lymphoma on 18F-FDG PET/CT

How equilibrium radionuclide angiography can quantify tricuspid regurgitation

BMIPP SPECT in cardiac sarcoidosis: A marker of risk?

Reverse redistribution-like change on dipyridamole-stress 99mTc-tetrofosmin imaging in a patient with angiographically mild coronary artery stenosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page